33119-72-1

Usage

Uses

Used in Pharmaceutical Industry:
1-AMINO-3,3-DIMETHYL-BUTAN-2-ONE HYDROCHLORIDE is used as a key intermediate in the synthesis of cyclin-dependent kinase 2 (CDK-2) inhibitors for their application as selective antitumor agents. These CDK-2 inhibitors play a crucial role in the regulation of the cell cycle and have shown potential in the treatment of various types of cancer by selectively targeting and inhibiting the activity of CDK-2, thereby preventing uncontrolled cell proliferation and tumor growth.

InChI:InChI=1/C6H13NO.ClH/c1-6(2,3)5(8)4-7;/h4,7H2,1-3H3;1H

Upstream product

• 56658-35-6 1-phthalimido-3,3-dimethyl-butan-2-one 
• 5469-26-1 1-Bromopinacolon 
• 13547-70-1 1-chloro-3,3-dimethyl-butan-2-one 
• 76779-98-1 1-azido-3,3-dimethyl-2-butanone 
• 171974-64-4 2,4-Bis(dimethylethyl)-2-methyl-2,5-dihydro-1H-imidazole 

Downstream Products

• 1333327-16-4 2-bromo-N,N'-bis-(3,3-dimethyl-2-oxobutyl)-isophthalamide 
• 345629-23-4 tert-butyl 4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-carbamoyl)piperidine-1-carboxylate 
• 345627-80-7 SNS-032 
• 333389-44-9 α-N-2-(chloroacetylamino)pinacolone 

Relevant academic research and scientific papers

MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES

An organic electronic device, preferably an organic light-emitting diode (OLED), comprising at least one metal-carbene complex comprising one, two or three specific bidentate diazabenzimidazole carbene ligands;a light-emitting layer comprising said metal-carbene complex as emitter material, preferably in combination with at least one host material;the use of said metal-carbene complex in an OLED;an apparatus selected from the group consisting of stationary visual display units, mobile visual display units, illumination units, units in items of clothing, units in handbags, units in accessoires, units in furniture and units in wallpaper comprising said organic electronic device, preferably said OLED, or said light-emitting layer;the metal-carbene complex comprising one, two or three specific bidentate diazabenzimidazole carbene ligands mentioned above and a process for the preparation of said metal-carbene complex.

Nitrogen Mustard Derivatives

The disclosure includes compounds of Formula (1): wherein X1, X2, Q, Z, R1, and R2 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

Long-range diastereoselectivity in an Ugi reaction: Stereocontrolled and diversity-oriented synthesis of tetrahydrobenzoxazepines

Salicylaldehydes and protected 1,2-amino alcohols have been convergently converted into a series of 2,3-dihydrobenzo[f][1,4]oxazepines, which undergo an Ugi-Joullie multicomponent reaction with unusual long-range diastereoselectivity. This protocol allows

Catalytic asymmetric hydrogenation of N-Boc-imidazoles and oxazoles

Substituted imidazoles and oxazoles were respectively hydrogenated into the corresponding chiral imidazolines and oxazolines (up to 99% ee). The highly enantioselective hydrogenation was achieved by using the chiral ruthenium catalyst, which is generated

CDK INHIBITORS

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.

NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION

The present invention relates to compounds of f formula (I) as cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2 ) receptor modulators, and uses thereof f or treating diseases, conditions and/or disorders modulated by a cannabinoid receptor ( such as pain, neurodegenrative disorders, eating disorders, weight loss or control, and obesity).

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).

N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl] -4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

N-Acyl-2-aminothiazoles with nonaromatic acyl side chains containing a basic amine were found to be potent, selective inhibitors of CDK2/cycE which exhibit antitumor activity in mice. In particular, compound 21 {N-[5-[[[5-(1,1-dimethylethyl)-2- oxazolyl]m

Concise synthesis of 1H-pyrazin-2-ones and 2-aminopyrazines

Convenient syntheses of 1H-pyrazin-2-ones and 2-aminopyrazines are described. By coupling Boc-protected amino acids with α-amino ketones or with amino alcohols and subsequent oxidation, 1H-pyrazin-2-ones were obtained. Transformation into the corresponding pyrazine triflates and substitution with primary or secondary amines led to 2-aminopyrazines. Since these syntheses take advantage of the use of readily available starting materials (e.g., amino acids, aminoalcohols and amines) a variety of the entitled structures can be obtained in few, high yielding steps.